Triple Quad LC/MS/MS Systems Enable New Levels of Sensitivity for Clinical Trials of Inhaled Drugs

AB Sciex have announced that the International Pharmaceutical Research Center (IPRC) in Jordan is investing in two AB Sciex Triple Quad™ 6500 LC/MS/MS Systems in order to offer new capabilities for bioanalysis studies of Phase I clinical trial compounds. The sensitivity of the 6500 Systems will enable the IPRC to detect drug compounds or metabolites in human samples down to femtogram levels for the first time, as well as increasing significantly the IPRC’s daily sample throughput.

“These two 6500 Systems will make a significant different to our capabilities as well as to our productivity,” said Dr Isam Salem, Vice President, Operations, IPRC. “We will be able to provide Phase I clinical trials for inhaled drugs and hormones for the first time, thanks to the extreme sensitivity of the 6500 Triple Quads. They will enable us to determine with confidence whether or not inhaled drugs are absorbed into the general circulation, even at the femtogram level.

“It’s critical that we have absolute confidence in the quality and robustness of our data when submitting clinical trials results to the regulatory bodies,” added Dr Salem. “We have always depended on AB Sciex hardware and software systems. We have a long and collaborative relationship with the company, based on its excellent support and high quality instruments, which have never once let us down.”

The 6500 System with Ion Drive™ Technology increases the quantity of ions produced while enhancing the way ions are transmitted and detected, increasing the limits of quantitation.

“Our customers depend on the reliability and performance of our instruments and software to obtain the answers they need to critical scientific questions,” said Khalid Ghaffar, Manager Sales HGM MENAm AB Sciex. “In turn, our local support teams strive to maintain collaborative relationships with our customers through delivering comprehensive and high quality technical support services.”